Predicting pre-eclampsia by Chappell, Lucy C. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1136/bmj.h6349
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Chappell, L. C., Sandall, J., Barnard, A. M., & McManus, R. J. (2015). Predicting pre-eclampsia. BMJ (Clinical
research ed.), 351, [h6349]. 10.1136/bmj.h6349
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
Predicting pre-eclampsia
A challenge that shouldn’t distract us from improving antenatal care across the board
Lucy C Chappell NIHR research professor in obstetrics 1, Jane Sandall professor of social science
and women’s health and NIHR senior investigator 1, Ann Marie Barnard chief executive 2, Richard
J McManus NIHR professor of primary care research 3
1Women’s Health Academic Centre, King’s College London, London SE1 7EH, UK; 2Action on Pre-eclampsia, Evesham, Worcestershire WR11
4EU, UK; 3Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK
A healthy mother and baby are the desired outcomes of all
antenatal care, yet WHO estimates that every year around the
world there are about 303 000 maternal deaths, 2.6 million
stillbirths, and 2.7 million neonatal deaths. Pregnancy and birth
are transformational life events, but optimal preparation for
transition to motherhood often receives little attention.
Pregnancy in itself is not an illness or a disease, but
comorbidities or evolving complications can lead to mortality
or serious morbidity. Risk stratification of pregnant women has
been proposed to enable increased surveillance and appropriate
prophylactic interventions for those at greater risk of
complications, while normalising healthy women who have a
high likelihood of uncomplicated pregnancy. The linked study
byMacdonald-Wallis and colleagues (doi:10.1136/bmj.h5948)
reports the development and validation of a new prediction
model for pre-eclampsia.3 They concluded that incorporating
routinely collected blood pressure measurements into models
based on early pregnancy maternal characteristics would
improve risk stratification, “facilitating a reduction in scheduled
antenatal care” for those at low risk of pre-eclampsia.
The current schedule for antenatal care in many high income
countries has a scant evidence base and focuses on one aspect
of medical input without necessarily considering the holistic
needs of the woman and her emergent family. Pre-eclampsia is
associated with a range of complications, including maternal
cerebrovascular events, hepatic and renal impairment, and
pulmonary oedema, any of which might be life threatening; it
is also associated with fetal growth restriction with attendant
increased risks of stillbirth and neonatal death in all settings.
For many years, hypertensive disorders of pregnancy have been
responsible for a substantial proportion of maternal deaths in
high and low income countries, alongside other causes such as
postpartum haemorrhageand deaths secondary to cardiac or
psychiatric comorbidities.Thus it remains an important goal to
predict and prevent pre-eclampsia to reduce avoidable morbidity
and mortality in both mother and baby, but we must not ignore
prediction and prevention of other adversematernal and perinatal
outcomes, and the promotion of health and wellbeing, if we are
to achieve and exceed the millennium development goals to
improve maternal health and reduce child mortality.
Around 70 risk prediction models have been reported for
pre-eclampsia, but few undergo external validation and none
has been tested against clinical judgment or routinely introduced
into widespread clinical practice.These latter issues are not
unique to this specialty; in the few cases where models have
been tested against clinical judgment they were rarely
superior.Decreased antenatal monitoring (potentially difficult
as many “low risk” women are in second pregnancies and
therefore already on a reduced schedule) might not be enough
to drive implementation of a predictionmodel for pre-eclampsia.
Prophylactic low dose aspirin, associated with a 17% reduction
in pre-eclampsia and 14% decrease in perinatal death,is already
recommended for women with known risk factors for
pre-eclampsia.
In the linked study,the proposed model formalises some of the
process that clinicians currently adopt informally at sequential
antenatal visits—that is, adapting their perception of ongoing
risk by incorporation of new information on blood pressure.
Themodel showed good test performance for ruling out disease;
for a fixed detection rate of 95% of cases, however, the positive
predictive value of the basic and enhanced model was low at
4-5%, a minimal increment on the pre-test incidence (2.9%) in
the population. As this model was developed and validated in
largely white European cohorts with mainly normal body mass
index, test performance in a more diverse population could lead
to reduced predictive values.
The proposed benefit therefore comes from downscaling visits
for the 30% of women who are judged by the model to be low
risk, but this would reduce the broader spectrum of antenatal
interactions that occur at each visit, not just those related to
pre-eclampsia. A Cochrane review on alternative packages of
antenatal care for low risk pregnant women found some evidence
from trials in low and middle income countries that reduced
visits might be associated with increased perinatal mortality;
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women in all settings were less satisfied with the reduced
schedule of visits, and for some women the gap between visits
was perceived as too long.
Alternatively, if the main purpose of the antenatal visit is solely
to obtain a blood pressure reading to exclude development of
pre-eclampsia, then the introduction of self monitoring of blood
pressure, empoweringwomen tomanage their own health, might
be more valuable. At present, we have insufficient data on the
validity or reliability of self monitoring in pregnancy, but it has
considerable potential.
Development of a high performance prediction model for
pre-eclampsia is challenging because pre-eclampsia is so
heterogeneous clinically. Expecting one test or model to predict
a condition that varies from severe early onset disease with fetal
growth restriction and a clear placental phenotype, to onset at
term in a mother with an appropriately grown fetus and
predominantlymaternal complications remains problematic,even
before comparison with clinical judgment. Antenatal care,
however, is about much more than obtaining two numbers
representing systolic and diastolic blood pressure. We should
re-examine much more holistically whether current schedules
of antenatal care are fit for purpose and give women everywhere
the best possible chance of a healthy pregnancy, a complication
free delivery, and a healthy baby.
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